Open access journal of the Ferrata-Storti Foundation, a non-profit organization
Letters to the Editor

The role of the K247R substitution in the ABL tyrosine kinase domain in sensitivity to imatinib

Vol. 91 No. 1 (2006): January, 2006

Abstract

Imatinib mesylate has become the gold standard front-line treatment of chronic myelogenous leukemia through its ability to inhibit ABL tyrosine kinase. Resistance to this inhibition may occur. We investigated the role of the K247R polymorphism in persistent sensitivity.

Figures & Tables

Article Information

Vol. 91 No. 1 (2006): January, 2006 : Letters to the Editor
 
DOI
 
Published
2006-01-01
Published By
Ferrata Storti Foundation, Pavia, Italy
Print ISSN
0390-6078
Online ISSN
1592-8721
 

Article Usage

Online Views
409
PDF Downloads
254
No Data
PlumX
Navigate
For Authors
For Reviewers
For Advertisers
Education
Privacy
More
Copyright © 2026 by the Ferrata Storti Foundation | Web design ￫ | Development ￫
ISSN 0390-6078 print | ISSN 1592-8721 online